Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1578-1584

  Otvos Jr , Laszlo ^a   Kovalszky, Ilona ^b   Riolfi, Mirko ^c   Ferla, Rita ^d   Olah, Julia ^b   Sztodola, Andras ^b   Nama, Kaushik ^a   Molino, Annamaria ^e   Piubello, Quirino ^f   Wade, John D ^g   Surmacz, Eva ^d  

^a Temple University   (United States)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UNIVERSITY OF VERONA   (Italy)

^d TEMPLE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f Pathology Department   (Italy)

^g FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Growth inhibition; Leptin; Obesity; Peptidomimetic drug; Subcutaneous drug administration; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; LEPTIN; LEPTIN RECEPTOR; PEPTIDE ALLO ACA; PEPTIDOMIMETIC AGENT; RECEPTOR BLOCKING AGENT; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; WEIGHT GAIN;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFUSIONS, SUBCUTANEOUS; LEPTIN; MICE; NEOPLASM TRANSPLANTATION; OBESITY; PEPTIDES; RECEPTOR, ERBB-2; RECEPTORS, LEPTIN; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958835946     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.018     Document Type: Article

References (34)

1. R. Dent, M. Trudeau, and K.I. Pritchard Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 2007 4429 4434 (Pubitemid 47219710)
2. S.M. Rodriguez-Pinilla, and D. Sarrio Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas Clin Cancer Res 12 2006 1533 1539
3. L. Vona-Davis, and D.P. Rose The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review J Womens Health (Larchmt) 18 2009 883 893
4. S.P. Kang, M. Martel, and L.N. Harris Triple negative breast cancer: current understanding of biology and treatment options Curr Opin Obstet Gynecol 20 2008 40 46
5. U. De Georgi, G. Rosti, and L. Frassinetti High-dose chemotherapy for triple negative breast cancer Ann Oncol 18 2007 202 203 (Pubitemid 46152527)
6. S.K. Pal, and J. Mortimer Triple-negative breast cancer: novel therapies and new directions Mauritas 63 2009 269 274
7. D.P. Silver, A.L. Richardson, and A.C. Eklund Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 2010 1145 1153
8. L. Vona-Davis, D.P. Rose, and M. Howard-McNatt Triple-negative breast cancer and obesity in a rural Appalachian population Cancer Epidemiol Biomarkers Prev 17 2008 3319 3324
9. B. Maiti, M.N. Kundranda, and T.P. Spiro The association of metabolic syndrome with triple-negative breast cancer Breast Cancer Res Treat 121 2010 479 483
10. A.I. Phipps, K.E. Malone, and P.L. Porter Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women Cancer Epidemiol Biomarkers Rev 17 2008 2076 2086
11. E. Surmacz Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res 9 2007 301
12. C. Garofalo, M. Koda, and S. Cascio Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli Clin Cancer Res 12 2006 1447 1453
13. V. Bartella, S. Cascio, and E. Fiorio Insulin-dependent leptin expression in breast cancer cells Cancer Res 68 2008 4919 4927
14. S. Cascio, V. Bartella, and A. Auriemma Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α Oncogene 27 2008 540 547
15. M.P. Cleary, M.E. Grossmann, and A. Ray Effect of obesity on breast cancer development Vet Pathol 47 2010 202 213
16. C. Garofalo, and E. Surmacz Leptin and cancer J Cell Physiol 207 2006 12 22
17. E. Fiorio, A. Mercanti, and M. Terrasi Leptin/HER2 crosstalk in breast cancer: in vitro study, preliminary in vivo analysis BMC Cancer 8 2008 305
18. M. Ishikawa, J. Kitayama, and H. Nagawa Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer Clin Cancer Res 10 2004 4325 4331 (Pubitemid 38878870)
19. A. Ray, and M.P. Cleary Leptin as a potential therapeutic target for breast cancer prevention and treatment Expert Opin Ther Targets 14 2010 443 451
20. X.H. Xia, J.C. Gu, and Q.Y. Bai Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features Chinese Med J 122 2009 3078 3081
21. L. Otvos Jr, M. Terrasi, and S. Cascio Development of a pharmacologically improved peptide agonist of the leptin receptor Biochim Biophys Acta 1783 2008 1745 1754
22. Otvos L Jr., Kovalszky I, Scolaro L, et al. Peptide-based receptor antagonists for cancer treatment and appetite regulation. Biopolymers Pept. Sci 2011; in press, doi:10.1002/bip.21377, PMID: 20564005.
23. Peelman.F. Van, L. Beneden, and H. Zabeau Mapping of the leptin binding sites and design of a leptin antagonist J Biol Chem 279 2004 41038 41046
24. S. Lee-Huang, P.L. Huang, and Y. Sun Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30 Anticancer Res 20 2000 653 659 (Pubitemid 30240615)
25. H. Rochefort, M. Glondu, and M.E. Sahla How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 10 2003 261 266 (Pubitemid 36758652)
26. C.J. Sweeney, S. Mehrotra, and M.R. Sadaria The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer Mol Cancer Ther 4 2005 1004 1012 (Pubitemid 40909083)
27. A. Ray, K. Nkhata, and M.P. Cleary Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status Int J Oncol 30 2007 1499 1509
28. F.P. O'Malley, T. Thomson, and J. Julian HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab Arch Pathol Lab Med 132 2008 61 65
29. M. Koda, M. Sulkowska, and A. Wincewicz Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer Ann N Y Acad Sci 1095 2007 90 98 (Pubitemid 47092441)
30. M. Riolfi, R. Ferla, and L. Del Valle Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy Brain Pathol 20 2010 481 489
31. P.N. Zannikos, S. Rohatagi, and B.K. Jensen Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM) J Clin Pharmacol 40 2000 1129 1140
32. E. Ostorhazi, F. Rozgonyi, and A. Sztodola Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections J Antimicrob Chemother 65 2010 2416 2422
33. S. Anagnostoulis, A.J. Karayiannakis, and M. Lambropoulou Human leptin induces angiogenesis in vivo Cytokine 42 2008 353 357
34. A. Bosch, P. Eroles, and R. Zaragoza Tripe-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat Rev 36 2010 206 215